subscribeSubscribe
Ironwood spies new frontier for $1B drug in exploratory trial

Ironwood spies new frontier for $1B drug in exploratory trial
FIERCE BIOTECH
29 Mar 2024
Share Share
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream
BUSINESSWIRE
10 Mar 2024
Share Share
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib
PR NEWSWIRE
10 Dec 2023
Share Share
Incyte defends Jakafi against competitor drugs, patent cliff

Incyte defends Jakafi against competitor drugs, patent cliff
Angus Liu FIERCE PHARMA
31 Oct 2023
Share Share
Incyte Announces New Data for Ruxolitinib in Children with Atopic Dermatitis

Incyte Announces New Data for Ruxolitinib in Children with Atopic Dermatitis
BUSINESSWIRE
13 Oct 2023
Share Share
Data from Incyte Phase 3 Program Demonstrates Efficacy of with Opzelura

Data from Incyte Phase 3 Program Demonstrates Efficacy of with Opzelura
BUSINESSWIRE
11 Oct 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Ruxolitinib Phosphate Cream

FDA Confirms Paragraph IV Patent Litigation for Ruxolitinib Phosphate Cream

FDA
21 Sep 2023
Share Share
Incyte skin disease cream for children meets main goal in late-stage study

Incyte skin disease cream for children meets main goal in late-stage study
REUTERS
12 Jul 2023
Share Share
Navtemadlin & Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis

Navtemadlin & Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis
ONCLIVE
08 Jul 2023
Share Share
MHRA Grants Marketing Authorisation for Opzelura for Non-Segmental Vitiligo

MHRA Grants Marketing Authorisation for Opzelura for Non-Segmental Vitiligo
BUSINESSWIRE
06 Jul 2023
Share Share